Lates News

In early trading on Monday, Merck fell 0.4% in U.S. stocks. The company reported that its daily PCSK9 inhibitor alirocumab can further reduce low-density lipoprotein by up to 60% compared to statins, with similar efficacy to injectables, potentially expanding the accessibility of intensified lipid-lowering therapy.